| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
Infliximab trough level; C-reactive protein; Fecal calprotectin; Crohn’s disease; Clinical remission; Long-term endoscopic outcomes |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Wan-Ting Cao, Rong Huang, Shan Liu, Yi-Hong Fan, Mao Sheng Xu, Yi Xu and Hui Ni |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81473506 |
| National Natural Science Foundation of China |
81971600 |
| Zhejiang TCM Science and Technology Project |
2019ZA056 |
| Zhejiang TCM Science and Technology Project |
2021ZA057 |
| Zhejiang TCM Science and Technology Project |
2016ZA077 |
|
| Corresponding Author |
Yi-Hong Fan, MD, Associate Professor, Chief Doctor, Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Key Laboratory of Gastrointestinal Diseases Pathophysiology, No. 54 Youdian Road, Shangcheng District, Hangzhou 310006, Zhejiang, China. yhfansjr@163.com |
| Key Words |
Infliximab trough level; C-reactive protein; Fecal calprotectin; Crohn’s disease; Clinical remission; Long-term endoscopic outcomes |
| Core Tip |
Previous investigations, contraposing Crohn’s disease patients under infliximab (IFX) maintenance therapy, have indicated that higher IFX trough levels (ITLs) were associated with sustained drug response and clinical remission in inflammatory bowel disease patients, while lower ITLs were linked to secondary unresponsiveness of IFX. Currently, endoscopic remission or mucosal healing has been considered the main goal of biological therapy. Our study manifested that Crohn’s disease patients with higher levels of IFX blood concentration and lower levels of inflammatory biomarkers tended to have a better long-term endoscopic prognosis. Combining ITL, fecal calprotectin and C-reactive protein monitoring was helpful for the timely adjustment of IFX treatment strategy. |
| Publish Date |
2022-06-16 13:07 |
| Citation |
Cao WT, Huang R, Liu S, Fan YH, Xu M, Xu Y, Ni H. Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy. World J Gastroenterol 2022; 28(23): 2582-2596 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i23/ 2582.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i23.2582 |
